At the forefront of the fight
against bacterial infections

• All years
• 2023
• 2022
• 2021

• 06/28/2023 - 22:05

  Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM

• 06/26/2023 - 22:00

  ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics

• 06/23/2023 - 20:45

  Pherecydes Pharma and Erytech Pharma shareholders approve the merger between the two companies

• 06/14/2023 - 20:00

  Commercial Court rejects Akkadian's request to postpone the merger vote: Pherecydes and Erytech shareholders will be able to vote on the merger on June 23, 2023

• 06/08/2023 - 07:30

  Pherecydes Pharma Has Submitted An Application For The Approval Of A Phase I Clinical Study In Infective Endocarditis Caused By Staphylococcus Aureus

• 06/05/2023 - 08:00

  Pherecydes announces that legal proceedings have been initiated against Erytech by Akkadian to obtain the postponement of the vote on the merger with Pherecydes

• 05/23/2023 - 22:53

  Availability of the Exemption document

• 05/16/2023 - 07:00

  PHERECYDES Strengthens its Corporate Links with ERYTECH to Prepare the Strategic Combination

• 04/17/2023 - 07:00

  Pherecydes Pharma presented its Phagogram 1.5 at the ECCMID Congress

• 04/06/2023 - 17:45

  TP ICAP Midcap initiates coverage of Pherecydes Pharma with a “Buy” recommendation

• 03/27/2023 - 07:00

  Pherecydes Pharma selected for the French Tech Health20 program’s 2023 class

• 01/25/2023 - 17:45

  Pherecydes Pharma announces its participation in several scientific and investor conferences

• 01/03/2023 - 17:45

  Pherecydes Pharma Announces its Financial Agenda for 2023

• 12/15/2022 - 18:00

  Pherecydes Pharma: minutes of the Combined General Meeting of December 15, 2022

• 11/29/2022 - 18:00

  Pherecydes Pharma announces the positive recommendation of the DSMB for the continuation of its phase II clinical study PhagoDAIR in osteoarticular infections caused by Staphylococcus aureus

• 11/16/2022 - 07:00

  Pherecydes Pharma will present its phagogram’s latest progress during an oral session at the Phage Futures US 2022 conference

• 10/27/2022 - 17:45

  Half-year 2022 financial results and update on the development plan

• 09/27/2022 - 18:00

  Pherecydes Pharma announces its participation in a number of major scientific and investor conferences

• 09/22/2022 - 08:30

  Pherecydes Pharma successfully completes €3.1 million capital increase

• 09/21/2022 - 17:35

  Pherecydes Pharma launches a capital increase for c. €3m to continue its clinical development program in phage therapy

• 09/15/2022 - 17:45

  Pherecydes Pharma announces the creation of an international Medical Advisory Board

• 09/12/2022 - 17:45

  Pherecydes Pharma announces a first registration of its phagogram as an in vitro diagnostic test in accordance with EC Directives

• 06/27/2022 - 07:00

  Positive preclinical results for inhaled phage therapy presented to the Reanimation 2022 conference

• 06/15/2022 - 18:00

  Pherecydes Pharma announces the enrollment of the first patient in the phase II study PhagoDAIR in the treatment of osteoarticular infections caused by Staphylococcus aureus

• 06/08/2022 - 18:00

  Pherecydes Pharma organizes a scientific symposium during the 23rd National Days of Infectiology

• 05/30/2022 - 18:00

  Pherecydes Pharma obtains AAC Early Access Program approval from the ANSM for its anti-Staphylococcus aureus phages

• 05/23/2022 - 19:00

  The general assembly of Pherecydes Pharma approves the evolution of its governance towards a company with a Board of Directors

• 04/28/2022 - 18:00

  Pherecydes Pharma announces the first international approval of a compassionate treatment with its phages

• 04/14/2022 - 07:00

  Pherecydes Pharma announces its 2021 annual financial results and confirms its 2022 outlook

• 04/07/2022 - 18:00

  Pherecydes Pharma announces the appointment of Thibaut du Fayet as Chief Operating Officer and member of the Executive Board

• 03/31/2022 - 07:00

  Pherecydes Pharma announces partnership with Navarrabiomed to evaluate its anti-S. aureus phages in a new indication

• 03/22/2022 - 07:00

  Pherecydes Pharma granted a new patent for its anti-Pseudomonas aeruginosa phages in Europe

• 03/11/2022 - 07:00

  Pherecydes Pharma and BIOASTER join forces in the treatment of bacteremia

• 03/08/2022 - 17:45

  Pherecydes Pharma extends its intellectual property in China with a first patent granted for its anti-Pseudomonas aeruginosa phages in this territory

• 02/24/2022 - 07:00

  Pherecydes Pharma announces a change in its governance structure to become a Company with a Board of Directors

• 02/07/2022 - 17:45

  Pherecydes Pharma receives a favorable opinion from the Ethics Committee to initiate the PhagoDAIR study

• 01/10/2022 - 17:45

  Pherecydes Pharma Announces its Financial Agenda for 2022

• 01/03/2022 - 18:00

  The PhagECOLI project undertaken by Pherecydes Pharma and the CEA receives a €2 million grant from Bpifrance

• 12/22/2021 - 07:00

  Pherecydes Pharma obtains ANSM approval for its PhagoDAIR program, the world’s first study in precision phage therapy

• 12/16/2021 - 07:00

  Pherecydes Pharma continues to strengthen its intellectual property with a first patent granted in China, for its anti-Staphylococcus aureus phages

• 11/29/2021 - 07:00

  First patent granted in Israel for anti-Staphylococcus aureus phages and update on the development schedule

• 10/20/2021 - 18:00

  Pherecydes Pharma announces the appointment of Dr. Pascal Birman as Medical Director

• 10/13/2021 - 07:00

  Pherecydes Pharma publishes its half-year 2021 financial results and assesses its positive development momentum

• 09/08/2021 - 17:45

  Pherecydes Pharma announces its participation in a number of major scientific conferences and investor events in H2 2021

• 06/16/2021 - 17:45

  Pherecydes Pharma will present its work on the provision of bacteriophages for therapeutic use at the France Bioproduction congress

• 06/07/2021 - 18:00

  The results of a preclinical trial demonstrating the benefits of inhaled Pherecydes Pharma phages in treating ventilation-associated pneumonia have been published in the prestigious British Journal of Pharmacology

• 05/11/2021 - 07:00

  Pherecydes Pharma expands its patent portfolio with a new patent granted in Hong Kong

• 05/06/2021 - 07:00

  A new scientific publication highlights the beneficial effect of Pherecydes Pharma phages in treating a case of prosthetic knee infection

• 04/29/2021 - 18:00

  Pherecydes Pharma obtains €2 million in non-dilutive financing from Bpifrance

• 04/28/2021 - 07:00

  Portzamparc initiates the coverage of Pherecydes Pharma

• 04/15/2021 - 07:00

  Pherecydes Pharma announces its 2020 annual financial results and confirms its 2021 outlook

• 04/08/2021 - 18:00

  A preclinical trial demonstrates the benefits of inhaled Pherecydes Pharma phages in treating ventilation-associated pneumonia

• 03/31/2021 - 18:00

  Pherecydes Pharma strengthens its Management Committee: recruitment of Céline Breda as Director of Industrial Operations

• 03/22/2021 - 18:00

  Pherecydes Pharma Announces its Financial Agenda for 2021

• 03/15/2021 - 18:00

  Pherecydes Pharma’s phage production project (PhagoPROD) featured in the European Commission’s CORDIS magazine

• 02/16/2021 - 18:00

  Strengthening of Pherecydes Pharma’s patent portfolio with two new patents granted in the United States

• 02/02/2021 - 20:27

  Resounding success of Pherecydes Pharma’s IPO on the Euronext Growth® market in Paris

• 01/29/2021 - 08:20

  Pherecydes Pharma brings forward the closing of its IPO to February 1, 2021, given its strong success with investors

• 01/05/2021 - 07:30

  Pherecydes Pharma announces its intention to list on the Euronext Growth® market in Paris